Dexcom, Inc.
$34.42B- Market cap
- $32.02B
- Debt
- +$3.32B
- Cash
- −$917.70M
Capital structure 91% equity / 9% debt · EV / Revenue 7.38x · EV / EBITDA 25.88x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $32.02B · View financials
Snapshot Sep 8, 2026, 3:01 PM ET
FY 2025 · Mkt cap
Decision snapshot: DXCM stock price at discount vs ICUI $84.84 current versus $11.24K implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ICUI's multiple
Implied fair value · at DXCM's multiple
Snapshot Sep 8, 2026, 2:59 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: DXCM FY 2025 (ended Dec 31, 2025) · ICUI FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 7.38x · EV / EBITDA 25.88x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 76% equity / 24% debt
DXCM carries the larger enterprise value at $34.42B against $5.32B; ICUI trades on the lower EV / Revenue multiple (2.38x vs 7.38x); ICUI on the lower EV / EBITDA (13.16x vs 25.88x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ICU MEDICAL INC/DE · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.21x
0.60x
Net debt / EBITDA
Leverage against operating earnings
1.81x
—
Cash and equivalents
Liquid reserves on the balance sheet
$917.70M
—
Total debt
Interest-bearing obligations outstanding
$3.32B
$1.28B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.